


# Squarex Pharma Signs Investment Term Sheet for Up to \$75 million To Go Public

SAINT PAUL, MINNESOTA, UNITED STATES, December 7, 2021

/EINPresswire.com/ -- [Squarex](#), LLC, announced today that it has signed a term sheet to go public with a notable health-care-focused institutional investor. The terms of the deal outlined would provide Squarex with up to \$75 million in financing. The transaction has several trigger points the first of which would be to take Squarex public via a reverse merger with a publicly listed company on the NASDAQ or NYSE that has yet to be identified. Concurrently with the public listing, the company will receive the first \$12.5 million tranche, with follow-on investment by the same firm of up to \$62.5 million.



Hugh McTavish and Squarex lab team

The money will be used to complete the Company's Phase IIb study, subsequent Phase III study, and provide the runway to commercialization. Squarex's drug SQX770 is unique in that a "single topical" application to the "arm (not the lip or face) has been shown in clinical trials to prevent cold sore outbreaks (oral [herpes](#)) for three months in people with frequent outbreaks. It acts by improving the body's natural immune response to the virus.

“

What a great day for Squarex and our investors! We are please to have the endorsement of such a high prestige investor. It's a real affirmation of years of hard work, and we are only getting started.”

*Hugh McTavish*

Hugh McTavish, Squarex's founder and CEO commented, “What a great day for Squarex and our investors! We are please to have the endorsement of such a high prestige investor. It's a real affirmation of years of hard work, and

we are only getting started.” Recently, Squarex engaged auditors Baker Tilly US LLP to undertake

a PCAOB audit of the company in preparation for going public.

Squarex has elected to keep its regulation Crowdfunding investment campaign on the [Wefunder](#) platform open while the company searches for a suitable company to reverse into and while the investment process moves toward final documentation. With the understanding that forward looking statements cannot be guaranteed, Wefunder investors would be buying in at a 30% discount to the stated valuation in the currently signed term sheet.

#### About Squarex Pharma

Squarex is a late clinical-stage biopharmaceutical company focused on the development and the

Company's commercialization of therapeutic candidates to address large market opportunities. Squarex is initially focused on the prevention of recurrent cold sores (herpes labialis) and other infections caused by Herpes Simplex Virus 1 or Herpes Simplex Virus 2. The Company's lead product candidate, SQX770, has successfully completed three clinical trials and shown significant efficacy in all three.

Squarex's drug SQX770 is unique. "A single topical application to the arm, (not the lip or face), has been shown in clinical trials to prevent cold sore outbreaks (oral herpes) in people with frequent outbreaks" for 3 months.

Investment Website: <https://Wefunder.com/squarexllc>

For more information about Squarex and partnering opportunities for its Herpes Labialis preventative treatment, please contact:

Joseph Cunningham, CFO, Squarex Pharma  
Tel 612 787-7281 [jcunningham@squarex-pharma.com](mailto:jcunningham@squarex-pharma.com)

Joseph Cunningham  
Squarex Pharma  
+1 612-787-7281  
[email us here](#)



Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/557629474>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.